IgniteIt · Cannabis Capital ConferenceMIAMI 2027March 24–26 · The Diplomat Beach Resort, Hollywood FL
The story behind the story.
Revenue Grew. Did Your Share of the Company Grow?
Cannabis spent years measuring success in revenue, stores, cultivation capacity and geographic footprint.
Our Chief Economic Columnist Rolando García went back through five years of SEC filings to ask a harder question: What happened to the capital required to produce that growth — and what was left for shareholders afterward?
The answer changes depending on where you look. One operator is now using cash to reduce its share count. Another is fighting over taxes paid years ago. Others have funded expansion with combinations of debt, equity and tax liabilities that can make headline growth look very different from per-share value creation.
This week, we follow the money.
— Nico Rodriguez, Managing Editor
Oct. 7 in Los Angeles Los Angeles Market Spotlight — register now
One Number
$668.4M
The uncertain-tax-position liability Trulieve reported at the end of 2025 — $630.3 million of it tied to its 280E position, according to Rolando’s review of the company’s filings.
That matters because operating cash flow doesn’t necessarily tell you where the cash ultimately belongs. When taxes are accrued but not paid, cash stays inside the business. It can fund operations and investment — but the liability remains.
Source: Company filings / Rolando García analysis
The Big Story
Follow the SEC Filings
For his latest IgniteIt analysis, Rolando García went through five years of public filings to examine something cannabis investors have spent years debating: Did expansion actually make existing shareholders better off?
He argues that a company can acquire another operator and increase revenue, build cultivation and add delivery hubs, open stores, enter states and report higher adjusted EBITDA. But somebody has to finance all of it.
That money can come from cash the business generates, new shares, debt, unpaid tax liabilities — or some combination of the four.
The denominator matters
That’s why Rolando argues that revenue growth needs to be read alongside share issuance, debt, capital expenditures, taxes and actual cash generation.
Adjusted EBITDA may exclude an impairment, but the money used to acquire the impaired asset was still spent.
Operating cash flow can look stronger while taxes remain unpaid.
Revenue can increase through acquisitions financed by debt or new shares.
And issuing stock can grow the enterprise while diluting the ownership of everyone already there.
The financial statements tell those stories. You just have to read them together.
Read Rolando’s five-year analysisThen Green Thumb Did the Opposite
This is where Green Thumb’s buyback becomes more interesting than the $50 million headline.
During the first six months of 2026, Green Thumb repurchased 13.44 million subordinate voting shares while issuing fewer than 2 million through RSU vesting, options and contractor compensation.
The result: shares outstanding fell from 206.63 million to 195.15 million — a 5.6% net reduction in six months.
In the framework Rolando lays out, that’s the other side of the denominator. Instead of issuing shares to fund growth, Green Thumb is using cash to remove them.
That doesn’t automatically make a buyback good capital allocation. The company still has to decide whether buying its own shares produces a better return than building stores, acquiring businesses, paying down debt or simply retaining cash.
But it gives investors a much better question than How much did they authorize? Did my percentage claim on the business actually increase?
See how Green Thumb’s buyback is changing its share count →
And Then There Are the Taxes
The same framework helps explain why the 280E fight is about more than tax rates.
In an exclusive interview with IgniteIt’s AJ Herrington, Adam Korenfield of CohnReznick Advisory examined the government’s attempt to recover an $8.3 million refund from TerrAscend after the company claimed $64.2 million in previously barred deductions.
The case raises a bigger question for cannabis balance sheets: Who ultimately owns the cash associated with old 280E positions?
That’s why Rolando warns against taking operating cash flow at face value. Cash generated from customers and cash retained because taxes haven’t been paid are not economically identical.
Read what the TerrAscend case could mean for past 280E taxes →
Partner InsightSponsored
From our partner, Azuca
Beyond Nano
Particle size has become one of the cannabis industry’s favorite explanations for fast-acting edibles. Azuca argues there’s more to the story.
Its new Beyond Nano white paper looks at what manufacturers should consider beyond particle size when evaluating fast-acting cannabinoid ingredients — including formulation, consistency, scalability and integration into commercial production.
Capital Allocation
Build, Buy — Or Buy Yourself?
That leaves cannabis executives with a problem the industry didn’t have much luxury to think about during the capital drought: What is the highest-return use of the next dollar?
Green Thumb can repurchase shares, Verano can invest in Virginia and Texas, and other operators can pursue acquisitions, pay down debt or preserve liquidity.
In our exclusive interview with Verano CEO George Archos, he described those choices explicitly: share repurchases, acquisitions and organic growth are competing for the company’s capital. Virginia is the more immediate opportunity — Archos called it Verano’s biggest organic growth driver for 2027.
“We’re trying to balance out the buckets and make sure we’re getting the best ROI for our shareholders.”
George Archos · CEO, Verano
As Rolando’s analysis suggests, the real question is what return shareholders are getting on the capital required to produce that growth.
The SpreadWeek 3 of 11
Curaleaf / AuroraAs of Sept. 29 close
10.1%Aurora’s discount
to offer value
to offer value
Aurora closed at $4.03 against consideration worth $4.48. Last week the gap was 7.8%.
66%Annualized return
if it closes
if it closes
66⅔%Tender threshold
Curaleaf set itself
Curaleaf set itself
62Days until
Dec. 1 expiry
Dec. 1 expiry
Why it matters: Aurora finished exactly where it was a week earlier, at $4.03. Curaleaf rose 3.2%. The offer is worth more, Aurora’s stock didn’t follow — and the discount widened from 7.8% to 10.1%.
We promised to follow the Curaleaf/Aurora spread through Dec. 1, so we’ll keep doing it.
Curaleaf wants to exchange cash and equity for Aurora’s international medical infrastructure, cultivation assets and future earnings. Aurora argues its shareholders should keep owning those assets independently.
So underneath the takeover mechanics is exactly the question we’re asking everywhere else this week: Which allocation of capital leaves shareholders with the more valuable claim on future cash flows?
Signals
Three Regulatory Numbers Worth Keeping
Three numbers from this week’s reporting are worth putting on the board.
71%
Massachusetts
That’s the share of likely voters who said they would vote against Question 8 — the ballot measure seeking to repeal the laws permitting adult-use cannabis sales and home cultivation — in the September Bay State Poll. Twenty-four percent supported the measure, and 5% were unsure. Read the poll →
12.5 oz
Nevada
New rules raise the amount a retailer can carry on a delivery trip from five ounces to 12.5, while doubling the minimum cannabis sample collected for lab testing from 10 grams to 20. More delivery capacity comes alongside new testing and compliance costs. Read the Nevada rules →
97%
California
The Department of Cannabis Control says 97% of cannabis seized in unincorporated areas came from counties that prohibit licensed cultivation. Assembly Majority Leader Cecilia Aguiar-Curry told AJ Herrington in an exclusive interview that stronger enforcement must go hand in hand with making compliance easier for small cultivators. Read the interview →
DW Alert
Register With the DEA — Or Wait?
The DEA has created a federal registration pathway for state-licensed medical cannabis operators, but Dickinson Wright says seven major categories of questions remain unresolved, from dual-use facilities and inventory to taxes, employees and federal inspections.
Registration could eventually offer meaningful advantages, including tax relief for qualifying medical operations and potentially other federal protections. But operators still don’t know how DEA registration will coexist with adult-use businesses operating from the same facilities, using the same employees and sharing inventory systems.
That turns registration into a management decision: Is the potential federal upside worth entering the system before the rules are settled — or is waiting the better business decision?
Analysis adapted from Dickinson Wright attorneys Jon Wachs, Ben Sobczak, Lloyd Pierre-Louis and Chris Lynch.
The Bottom Line
Growth isn’t the same thing as value.
Last week we suggested you stop counting stores. This week we take it one step further: stop measuring revenue without asking what it cost to produce.
A company can double revenue while issuing enough shares that existing investors own a smaller piece of the business. It can report operating cash while tax liabilities accumulate. It can report adjusted EBITDA while excluding impairments on assets somebody paid real money to acquire. It can shrink instead of expand, preserve liquidity — and still face the question of whether the remaining business can eventually support itself.
Let’s do the math: Start with cash. Subtract what the business needs to maintain itself. Account for taxes. Then look at debt, dilution and every other claimant standing between that cash and the common shareholder. Only then ask whether growth created value.
Green Thumb shrinking its share count, TerrAscend fighting over an old tax refund and Verano weighing buybacks against acquisitions and new markets look like separate stories. They’re different answers to the same question:
What is the next dollar worth — and who gets it?
Tell us: When you evaluate a cannabis operator, which number do you trust most — revenue growth, adjusted EBITDA, free cash flow or value per share? Email the desk — we’ll run the best answers.
Upcoming IgniteIt Events
Los Angeles Market SpotlightOct 7 · Los Angeles
Cannabis Capital & Policy SummitNov 18 · Washington, D.C.